Clofazamine (Lamprene)
Clofazamine
Novartis South Africa (Pty) Ltd
Registration
- Applicant
- Novartis South Africa (Pty) Ltd
- Certificate holder
- Novartis
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Lamprene 50 EACH CAPSULE CONTAINS :CLOFAZIMINE 50,0 mg | 50Gelatine capsules | 53047253/20.2.4/0472Approved 22 August 2024 | Registered | Not determined | PIPIL |
| Lamprene 100 EACH CAPSULE CONTAINS: CLOFAZIMINE 100 mg | 100Gelatine capsules | B0108B/20.2.4/108Approved 22 August 2024 | Registered | Not determined | PIPIL |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
No structure available
This product's active ingredient could not be matched to a single known compound.
SAHPRA documents
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.